X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Strides Arcolab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs STRIDES SHASUN LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA STRIDES SHASUN LTD TORRENT PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 44.2 36.3 121.7% View Chart
P/BV x 6.2 0.9 692.0% View Chart
Dividend Yield % 0.8 1.1 74.8%  

Financials

 TORRENT PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
STRIDES SHASUN LTD
Mar-17
TORRENT PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs1,5501,275 121.6%   
Low Rs1,144918 124.6%   
Sales per share (Unadj.) Rs354.7389.6 91.0%  
Earnings per share (Unadj.) Rs40.128.0 143.3%  
Cash flow per share (Unadj.) Rs64.248.9 131.3%  
Dividends per share (Unadj.) Rs14.004.50 311.1%  
Dividend yield (eoy) %1.00.4 253.3%  
Book value per share (Unadj.) Rs273.1303.1 90.1%  
Shares outstanding (eoy) m169.2289.42 189.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.82.8 134.9%   
Avg P/E ratio x33.639.2 85.7%  
P/CF ratio (eoy) x21.022.4 93.5%  
Price / Book Value ratio x4.93.6 136.3%  
Dividend payout %34.916.1 217.1%   
Avg Mkt Cap Rs m227,89798,036 232.5%   
No. of employees `00014.75.8 253.4%   
Total wages/salary Rs m11,3535,881 193.0%   
Avg. sales/employee Rs Th4,083.06,005.9 68.0%   
Avg. wages/employee Rs Th772.31,014.0 76.2%   
Avg. net profit/employee Rs Th461.3431.2 107.0%   
INCOME DATA
Net Sales Rs m60,02134,834 172.3%  
Other income Rs m2,9881,686 177.3%   
Total revenues Rs m63,00936,520 172.5%   
Gross profit Rs m13,4936,428 209.9%  
Depreciation Rs m4,0861,872 218.3%   
Interest Rs m3,0852,269 135.9%   
Profit before tax Rs m9,3103,973 234.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m2,529470 538.0%   
Profit after tax Rs m6,7812,501 271.2%  
Gross profit margin %22.518.5 121.8%  
Effective tax rate %27.211.8 229.6%   
Net profit margin %11.37.2 157.4%  
BALANCE SHEET DATA
Current assets Rs m52,62338,165 137.9%   
Current liabilities Rs m52,02230,402 171.1%   
Net working cap to sales %1.022.3 4.5%  
Current ratio x1.01.3 80.6%  
Inventory Days Days12077 154.6%  
Debtors Days Days76104 73.0%  
Net fixed assets Rs m85,01637,639 225.9%   
Share capital Rs m846894 94.6%   
"Free" reserves Rs m45,37626,210 173.1%   
Net worth Rs m46,22227,105 170.5%   
Long term debt Rs m41,11516,377 251.0%   
Total assets Rs m142,43281,168 175.5%  
Interest coverage x4.02.8 146.1%   
Debt to equity ratio x0.90.6 147.2%  
Sales to assets ratio x0.40.4 98.2%   
Return on assets %6.95.9 117.9%  
Return on equity %14.79.2 159.0%  
Return on capital %14.212.1 117.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58013,465 108.3%   
Fx outflow Rs m3,6004,076 88.3%   
Net fx Rs m10,9809,389 116.9%   
CASH FLOW
From Operations Rs m8,9422,881 310.3%  
From Investments Rs m-47,070-7,051 667.5%  
From Financial Activity Rs m34,1743,382 1,010.4%  
Net Cashflow Rs m-3,655-788 464.1%  

Share Holding

Indian Promoters % 71.5 27.7 258.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 37.8 18.6%  
FIIs % 12.6 8.6 146.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 25.9 34.0%  
Shareholders   26,511 56,241 47.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   ABBOTT INDIA  ALKEM LABORATORIES  AJANTA PHARMA  PFIZER  ALEMBIC PHARMA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Up Over 240 Points; Rupee Touches Record Low(12:30 pm)

After opening the day in the green, stock markets in India have continued their momentum and are presently trading on a positive note.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Should You Buy These Mouthwatering High Dividend Stocks?(Profit Hunter)

Aug 1, 2018

Many stocks are yielding dividends even upwards of 4%-5%. Here are the kinds you should pick, and the ones to avoid.

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

NFO - Axis Equity Hybrid Fund: A Worthy Proposition?(Outside View)

Aug 1, 2018

PersonalFN explains if NFO: Axis Equity Hybrid Fund, would be a worthy proposition currently.

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 14, 2018 01:45 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - NATCO PHARMA COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS